Login / Signup

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.

Niamh ColemanKathrina L MarceloJulia F HopkinsNusrat Israr KhanRobyn R DuLingzhi HongEdward ParkBinaifer BalsaraMollie LeoniCurtis R PickeringJeffrey N MyersJohn Victor HeymachLee A AlbackerDavid S HongMaura GillisonXiuning Li
Published in: JCO precision oncology (2023)
-mutant in HNSCC is distinct, which may provide insight to future therapeutic combination strategies.
Keyphrases
  • current status
  • clinical trial
  • randomized controlled trial
  • wild type
  • phase iii
  • open label
  • study protocol